Insight journal - Company

Lundbeck: Bravely battling brain diseases

Posted on 07 January 2014

Tags: , , ,

Top 50 Pharma company Lundbeck is researching, developing and marketing medications for the treatment of brain diseases. The Danish based company has products that target over 700m cases of brain diseases that are reported each year including depression, anxiety, psychotic disorders, epilepsy and Alzheimer’s.  The company employs over 5,800 people worldwide in 57 countries and is continually developing further products for the CNS market that currently has many diseases with unmet medical solutions.

Lundbeck’s research and coverage of brain diseases and neuroscience is truly vast, the company works on treatments at all development stages treating the following medical areas:

  • Alcohol dependence
  • Alzheimer’s disease
  • Epilepsy
  • Huntington’s disease
  • Mood disorders
  • Parkinson’s disease
  • Psychosis
  • Stroke

The company is very researched orientated; not only does it currently have over 1,200 employees working in the r&d departments, it also invests 20% of its annual revenue back into the research of new pharmaceutical products. In addition to Denmark where the company is headquartered the company has research centres and productions facilities in China and the USA. The company has a very healthy development pipeline with 5 phase II products targeted at treating stroke, psychiatric disorders, psychosis, epilepsy and alzheimer’s disease. It also has a product that is about to hit the market aimed at treating depression and anxiety.

Lundbeck was formed in 1915 by Hans Lundbeck as all rounder company selling many products from synthetic sugar to aluminium foil and photographic equipment. It was only in the 1920’s that it added pharmaceuticals to its production pipeline. The company only acquired its CNS focus following the death of founder Hans Lundbeck when the company began to develop psychopharmaceuticals. The company continued to expand and decide to phase out all other departments and concentrate solely on pharmaceuticals. Success continued for the company and from the 1990’s the company was catapulted even higher after it launched its breakthrough product Cipramil for the treatment of depression. Cipramil became registered in over 70 countries and afforded Lundbeck to acquire US base Synaptic and initiate a number of licensing deals to bring in new CNS compounds. The last two decades has seen further acquisitions and products launches that have rightly placed Lundbeck in the top 50 pharmaceuticals of today.

Partnering with Lundbeck

Partnerships remain a core component of Lundbeck’s business model; the company constantly strives to gain increased value from existing partnerships and actively seeks and evaluates external opportunities. Lundbeck is seen an attractive option to many potential partners due to its expertise in brain diseases teamed with its strong clinical and commercialization capabilities. The company has experience in partnering at all stages of development and is proven at integrating partnered products into its value chain. To effectively evaluate incoming opportunities Lundbeck has a placed a structured four stage process in place which involves an initial evaluation, full evaluation, due diligence and negotiation. This enables fast qualitative decisions to be made within the licensing team. At present Lundbeck is partnered with a number of global pharma companies including Forest Laboratories, Takeda Pharma, Merck and Kyowa Hakko Kirin.

To gain access to the best matched products from the very start Lundbeck states that it is looking for products at all stages of the development pipeline for medications related to the treatment of brain diseases. The company is open to all types of partnering agreements including in-licensing, co-development, strategic alliances and joint ventures. To contact Lundbeck for any potential partnerships you can contact...

Partnering outreach

Lundbeck is often present at a large number of partnering events throughout the year. Partnering events are a great place to meet lots of potential partners face to face in a short space of time.

Events with Lundbeck presence include but are not limited to:

  • BIO International Convention and Business Forum
  • BioEurope / BioEurope Spring

For a full list of forthcoming partnering events where you could meet with Lundbeck in person visit Current Partnering’s Event calendar. 

Contacting Lundbeck for partnering

Lundbeck can be contacted in relation to partnering through a number of channels. Here is a list of the most common channels: 

Partnering events: face to face contact is generally considered the most effective form of contact. Partnering events not only allow face to face contact but also contact with multiple companies for the price of one flight and hotel reservation. This benefit makes partnering events the most cost effective method of making personal introductions as a start point for partnering discussions.

See Current Partnering’s event calendar for details of forthcoming events. 

Direct contact: there are several sources of direct contact with Lundbeck’s business development team

-        Phone: Picking up the phone and speaking with an individual is the best form of non-face to face contact as it allows your name and voice to be remembered and associated with an opportunity.

-        Email: Sending an email is another good way of making contact. Ideally, research the individual responsible for the therapy/technology area being targeted and get in touch. See the website for details.

-        LinkedIn: Business to business contact is increasingly taking place via LinkedIn, the global online networking channel.

Many of Lundbeck’s business development executives have LinkedIn profiles and can be found by viewing the company’s profile. Visit Lundbeck’s LinkedIn page here.  

Opportunity submission form: the least favourable channel but worth using if you do not have access to the other channels mentioned above. This is the form available on the Lundbeck Pharmaceutical website for potential partnering opportunities. 

Raveena Bhambra 

* www.Lundbeck.com

More

Lundbeck Company profile
Partnering Activity for Lundbeck 2005 – 2013
M&A activity for Lundbeck 2005 – 2013

 

Available reports from Current Partnering

Report: Partnering Deals and Alliances with Lundbeck

Report: Top 50 Big Pharma Partnering and M&A Deal Trends

 

Available resources for deal coverage for Lundbeck

Subscribe: Current Agreements life sciences partnering, M&A and financing deals database – find out more

Read: more on Lundbeck company profile, recent partnering, M&A and financing news and articles

 

Related

Report: Practical Guide to Finding Partners

View: Current Partnering’s Partnering Scorecard – view top life science partnering deals by value

View: Current Partnering’s M&A Scorecard – view top life science M&A deals by value

View: Current Partnering’s Deal Metrics – the latest deal trend infographics for life science deal making

View: Current Partnering’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity

Signup: Current Partnering Dealmakers Update – weekly newsletter providing the latest life science industry deal news, deal making trends, partnering events – sign up now

Signup: Current Agreements Deals Review – monthly newsletter - reviewing the previous month’s life science deal making – partnering, M&A and financing – sign up now

View: Top 50 pharma – overview of top 50 pharmaceutical companies by revenue – partnering activity, deal news, partnering dealtalk

View: Top 50 biotech – overview of top 50 biotechnology companies by revenue – partnering activity, deal news, partnering dealtalk

Print Friendly, PDF & Email

Leave a Reply

 

cabannerad300x150new4gif
rauconbadgejpg
e80banner300x150animgif
cpbannerad300x150new2gif
rauconbadgejpg
a1banner300x150animgif